Full Text View
Tabular View
No Study Results Posted
Related Studies
Database of Interstitial Lung Diseases
This study is ongoing, but not recruiting participants.
First Received: December 19, 2005   Last Updated: August 7, 2008   History of Changes
Sponsored by: St. Antonius Hospital
Information provided by: St. Antonius Hospital
ClinicalTrials.gov Identifier: NCT00267800
  Purpose

The cause of most interstitial lung diseases (ILDs) is still unknown. Further research, for example to determine predisposing genetic factors, is therefore needed. A database with relevant clinical data and DNA/serum samples of ILD patients could facilitate future research on the cause of ILDs.


Condition
Interstitial Lung Diseases

U.S. FDA Resources
Study Type: Observational
Official Title: Registration of Clinical Data and DNA/Serum of Patients With Interstitial Lung Diseases (ILD)

Further study details as provided by St. Antonius Hospital:

Estimated Enrollment: 100000
Study Start Date: January 2006
Detailed Description:

Protocol title: 'Registration of clinical data and DNA of patients with Interstitial Lung Disease (ILD)' Rationale: The etiopathogenesis of most Interstitial Lung Diseases (ILDs) is still unknown. Further research, e.g. to determine predisposing genetic factors, is therefore needed. A database with relevant clinical data and DNA/serum samples of ILD patients could facilitate future research on the etiopathogenesis of ILDs. Objective: Availability of relevant clinical data and DNA/serum samples of ILD patients in a database. Those data can be used for future research.

Study design: A prospective observational study

Study population: Patients diagnosed with ILD attending the pulmonology department in participating hospitals.

Intervention: a blood sample is taken from each patient. Furthermore, additional information is collected from the medical file.

Main study parameters/endpoints: DNA and serum sample, demographic variables, medical information, occupational history and hobbies.

Nature and extent of the burden and risks associated with participation, group relatedness: two tubes of blood will be drawn from the patients. The risks of drawing blood from a vein are minimal.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of an ILD, as stated by the American Thoracic Society (ATS)
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00267800

Locations
Netherlands
St. Antonius Hospital
Nieuwegein, Netherlands, 3435CM
UMC Utrecht
Utrecht, Netherlands, 3584 CX
Mesos Medisch Centrum
Utrecht, Netherlands, 3527 CE
Diakonessenhuis
Utrecht, Netherlands, 3508 TG
Sponsors and Collaborators
St. Antonius Hospital
Investigators
Principal Investigator: J.M.M. van den Bosch, M.D. St. Antonius Hospital
Principal Investigator: J.C. Grutters, M.D. St. Antonius Hospital
  More Information

Additional Information:
No publications provided

Study ID Numbers: R05.08/A
Study First Received: December 19, 2005
Last Updated: August 7, 2008
ClinicalTrials.gov Identifier: NCT00267800     History of Changes
Health Authority: Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)

Keywords provided by St. Antonius Hospital:
Lung disease, Interstitial
Sarcoidosis
Pulmonary fibrosis

Study placed in the following topic categories:
Lung Diseases, Interstitial
Respiratory Tract Diseases
Fibrosis
Lung Diseases
Sarcoidosis
Pulmonary Fibrosis

Additional relevant MeSH terms:
Lung Diseases, Interstitial
Respiratory Tract Diseases
Lung Diseases

ClinicalTrials.gov processed this record on May 07, 2009